Compare EXPO & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXPO | IRON |
|---|---|---|
| Founded | 1967 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 1996 | 2020 |
| Metric | EXPO | IRON |
|---|---|---|
| Price | $56.69 | $68.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $88.00 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 546.6K | 439.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.87% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $582,014,000.00 | N/A |
| Revenue This Year | $12.75 | N/A |
| Revenue Next Year | $8.50 | $283.52 |
| P/E Ratio | $93.85 | ★ N/A |
| Revenue Growth | ★ 4.21 | N/A |
| 52 Week Low | $51.91 | $40.00 |
| 52 Week High | $81.95 | $99.50 |
| Indicator | EXPO | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 40.20 | 50.91 |
| Support Level | $51.91 | $64.39 |
| Resistance Level | $73.75 | $71.85 |
| Average True Range (ATR) | 1.90 | 3.10 |
| MACD | 0.11 | -0.19 |
| Stochastic Oscillator | 34.33 | 48.13 |
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.